Key result
Right ventricular insertion site fibrosis was associated with a 2.1-fold increased risk of heart failure admission or death in patients with dilated cardiomyopathy.
Why the study?
Right ventricular insertion site fibrosis is commonly seen on CMR in DCM, but without objective criteria has been considered a non-specific finding with poorly defined clinical relevance.
Does the presence of right ventricular insertion site fibrosis on CMR predict heart failure admission or death in patients with dilated cardiomyopathy?
Cohort (n=645)
No
Does the presence of right ventricular insertion site fibrosis on CMR predict heart failure admission or death in patients with dilated cardiomyopathy?
Hazard Ratio: 2.11 (95% CI 1.48–2.99)
Absolute Event Rate: 28% vs 14%
p-value: p=<0.001
Right ventricular insertion site fibrosis on CMR is an independent predictor of heart failure admission or death in patients with dilated cardiomyopathy, representing an intermediate risk phenotype.
No takes yet. Share an insight, caveat, or question.
May enhance DCM risk stratification on CMR; hypothesis-generating for therapeutic targeting.
Mikami et al. (2021) conducted a cohort in Dilated cardiomyopathy (n=645). Right ventricular insertion site fibrosis vs. Absence of right ventricular insertion site fibrosis was evaluated on Composite of heart failure admission or death (HR 2.11, 95% CI 1.48-2.99, p=<0.001). Right ventricular insertion site fibrosis was associated with a 2.1-fold increased risk of heart failure admission or death in patients with dilated cardiomyopathy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: